Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects

被引:20
作者
Zhou, XJ [1 ]
Lloyd, DM [1 ]
Chao, GC [1 ]
Brown, NA [1 ]
机构
[1] Idenix Pharmaceut Inc, Cambridge, MA 02139 USA
关键词
telbivudine; hepatitis B; antiviral; pharmacokinetics; food effect;
D O I
10.1177/0091270005284849
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The influence of food on the pharmocokinetics of telbivudine, a candidate antiviral agent against hepatitis B virus (HBV), was investigated in healthy adult following a 600-mg oral dose administered with and without a high-fat/high-calorie meal. Telbivudine was well tolerated under fasting and fed conditions. Oral absorption of telbivudine as measured by maximum plasma concentration (C-max), time to reach C-max (T-max) and area under the plasma concentration-time curve (AUC(0-t) and AUC(0-infinity)) was not altered by food intake immediately before oral dosing. Values of C-max, T-max, and AUC were comparable when telbivudine was administered Underfed and fasting conditions. Results from this study indicated that the absorption of telbivudine was not affected by a high-fat/high-calorie meal; telbivudine can therefore be administered orally with no regard to the timing of meals.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 23 条
[1]   PHARMACOKINETICS OF 3TC (GR109714X) ADMINISTERED WITH AND WITHOUT FOOD TO HIV-INFECTED PATIENTS [J].
ANGEL, JB ;
HUSSEY, EK ;
HALL, ST ;
DONN, KH ;
MORRIS, DM ;
MCCORMACK, JP ;
MONTANER, JSG ;
RUEDY, J .
DRUG INVESTIGATION, 1993, 6 (02) :70-74
[2]  
Bridges EG, 2003, FRONTIERS IN VIRAL HEPATITIS, P263, DOI 10.1016/B978-044450986-4/50073-4
[3]  
BRIDGES EG, 2001, ANTIVIR RES, P84
[4]  
Bryant M., 1999, ANTIVIR THER, V4, pA124
[5]   Antiviral L-nucleosides specific for hepatitis B virus infection [J].
Bryant, ML ;
Bridges, EG ;
Placidi, L ;
Faraj, A ;
Loi, AG ;
Pierra, C ;
Dukhan, D ;
Gosselin, G ;
Imbach, JL ;
Hernandez, B ;
Juodawlkis, A ;
Tennant, B ;
Korba, B ;
Cote, P ;
Marion, P ;
Cretton-Scott, E ;
Schinazi, RF ;
Sommadossi, JP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :229-235
[6]   Abacavir: Absolute bioavailability, bioequivalence of three oral formulations, and effect of food [J].
Chittick, GE ;
Gillotin, C ;
McDowell, JA ;
Lou, Y ;
Edwards, KD ;
Prince, WT ;
Stein, DS .
PHARMACOTHERAPY, 1999, 19 (08) :932-942
[7]   Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads [J].
Damle, BD ;
Yan, JH ;
Behr, D ;
O'Mara, E ;
Nichola, P ;
Kaul, S ;
Knupp, C .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (04) :419-427
[8]   COST-EFFECTIVENESS OF ONCE-DAILY ORAL ANTIMICROBIAL THERAPY [J].
DAVEY, P ;
PARKER, S .
JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 32 (08) :706-710
[9]   Pharmacology of β-L-thymidine and β-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes:: Relevance to chemotherapeutic efficacy against hepatitis B virus [J].
Hernandez-Santiago, B ;
Placidi, L ;
Cretton-Scott, E ;
Faraj, A ;
Bridges, EG ;
Bryant, ML ;
Rodriguez-Orengo, J ;
Imbach, JL ;
Gosselin, G ;
Pierra, C ;
Dukhan, D ;
Sommadossi, JP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1728-1733
[10]   Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection [J].
Kaul, S ;
Christofalo, B ;
Raymond, RH ;
Stewart, MB ;
Macleod, CM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2295-2298